Person: ÖZER, SIDIKA AYŞE
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
ÖZER
First Name
SIDIKA AYŞE
Name
5 results
Search Results
Now showing 1 - 5 of 5
Publication Open Access GENDER DIFFERENCES IN CLINICAL FEATURES AND BURDEN IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER: PRELIMINARY REPORT(BMJ PUBLISHING GROUP, 2021-06) DURUÖZ, MEHMET TUNCAY; Duruoz, M. T.; Ozer, A.; Gezer, H. H.; Melikoglu, M. Alkan; Hizmetli, S.; Baklacioglu, H. S.; Sahin, N.; Oz, N.; Gursoy, D. Erdem; Altintas, D.; Oba, P.; Kasman, S. AcerPublication Open Access SUBCLINICAL INFLAMMATION AND RELATED PARAMETERS IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER(BMJ PUBLISHING GROUP, 2020-06) DURUÖZ, MEHMET TUNCAY; Duruoz, M. T.; Oz, N.; Ozer, A.; Gezer, H. H.; Gursoy, D. Erdem; Kasman, S. AcerPublication Open Access EVALUATION OF CLINICAL FEATURES IN PATIENTS DIAGNOSED WITH JUVENILE AND ADULT-ONSET FAMILIAL MEDITERRANEAN FEVER(BMJ PUBLISHING GROUP, 2020-06) DURUÖZ, MEHMET TUNCAY; Gursoy, D. Erdem; Gezer, H. H.; Kasman, S. Acer; Oz, N.; Ozer, A.; Duruoz, M. T.Publication Open Access REGIONAL DIFFERENCES IN DISEASE CHARACTERISTICS OF FAMILIAL MEDITERRANEAN FEVER IN TURKEY: PRELIMINARY REPORT(BMJ PUBLISHING GROUP, 2021-06) DURUÖZ, MEHMET TUNCAY; Duruoz, M. T.; Gezer, H. H.; Melikoglu, M. Alkan; Hizmetli, S.; Baklacioglu, H. S.; Sahin, N.; Ozer, A.; Oz, N.; Gursoy, D. Erdem; Altintas, D.; Oba, P.; Kasman, S. AcerPublication Metadata only PIK3CA and TP53 MUTATIONS and SALL4, PTEN and PIK3R1 GENE EXPRESSION LEVELS in BREAST CANCER(WALTER DE GRUYTER GMBH, 2020) KAYA, HANDAN; Dirican, Ebubekir; Seven, Ipek Erbarut; Kaya, Handan; Ugurlu, M. Umit; Peker, Irem; Gulluoglu, Bahadir M.; Ozer, Ayse; Akkiprik, MustafaObjective: A high frequency of PI3K signalling pathway abnormalities and TP53 mutations are critical in the development and progression of breast cancer (BCa). We aimed to detect PIK3CA and TP53 mutations via an expression analysis of PIK3R1, PTEN and SALL4 and correlate the expression of these genes with clinical parameters of BCa. Materials and methods: PIK3CA and TP53 mutations in BCa samples were analysed by High-Resolution Melting (HRM) analysis, followed by Sanger sequencing, and the expression levels of PIK3R1, PTEN and SALL4 were evaluated by RT-PCR methods. Results: The frequency of PIK3CA and TP53 mutations was 42% and 38% according to the HRM and Sanger sequencing. There was a significantly high frequency of these mutations in ER(+), N0 and HER2(-) tumour samples. PIK3R1 and PTEN expression levels were high in tumour samples, whereas SALL4 expression was low. In patients with TP53 mutations, PIK3R1 expression was low, and this finding was statistically significant. PIK3R1 and PTEN expression levels showed statistically significant, respectively in G3 grades, ER(+), (PR)(+), HER2(+) and ER(+). Conclusions: We suggest that these candidate genes could be potential prognostic biomarkers of BCa and that they should be considered in the evaluation of clinical parameters of BCa.